Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The ...
The 2011 loss per share of 49 cents missed the Zacks Consensus Earnings Estimate of 10 cents, but was narrower than the year-ago loss of $3.48 per share. Excluding the impact of stock-based ...
Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback